Clinical Trial Update: A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC [Phase 1, Phase 2]

View source ↗

Summary

This is a clinical trial update for SHR-1501 alone or in combination with BCG or SHR-1316 in high-risk non-muscle invasive bladder cancer (NMIBC), Phase 1/2, cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (Bacillus Calmette-Guérin)
• SHR-1316
• SHR-1501

Snippet

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Conditions: High-risk NMIBC | Phase 1, Phase 2 | Status: RECRUITING